دورية أكاديمية
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1
| العنوان: | PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 |
|---|---|
| المؤلفون: | Filippo de Braud, Valter Torri, Giuseppe Lo Russo, Claudia Proto, Roberto Ferrara, Monica Ganzinelli, Marina Chiara Garassino, Giuseppe Viscardi, Giorgio Trinchieri, Mario Occhipinti, Rita Leporati, Marta Brambilla, Luca Agnelli, Silvia Brich, Francesco Sgambelluri, Roberta Mortarini, Andrea Anichini, Leonardo Provenzano, Daniele Lorenzini, Arsela Prelaj, James Dolezal, Teresa Beninato, Tiziana Triulzi, Alessandra Fabbri, Laura Mazzeo, Andrea Spagnoletti, Vanja Miskovic, Alessandra Laura Giulia Pedrocchi, Francesco Trovo', Sara Manglaviti, Claudia Giani, Paolo Ambrosini, Andrea Franza, John McCulloch, Tommaso Torelli, Giancarlo Pruneri |
| المصدر: | Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023) |
| بيانات النشر: | BMJ Publishing Group, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Background Chemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2051-1426 24665983 |
| Relation: | https://jitc.bmj.com/content/11/6/e006833.full; https://doaj.org/toc/2051-1426 |
| DOI: | 10.1136/jitc-2023-006833 |
| URL الوصول: | https://doaj.org/article/0391ecab2ee246659837c5b760a7cc74 |
| رقم الأكسشن: | edsdoj.0391ecab2ee246659837c5b760a7cc74 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20511426 24665983 |
|---|---|
| DOI: | 10.1136/jitc-2023-006833 |